Pure Global
NCT05733325

Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hypercholesterolemia
Study type
Observational
Sponsor & location
Primary sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Location
Torrance, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 18, 2021
End date
May 01, 2024
Enrollment
100 participants
Primary outcome

Percent change in total non-calcified coronary plaque volume

Summary

This is an observational study examining the progression of subclinical coronary
 atherosclerosis in healthy participants who have an elevated LDL-C (above 190mg/dl) secondary
 to diet not associated with genetic familial hypercholesterolemia (FH). This study
 participants are classified to be Lean-Mass-Hyper-Responder (LMHR).

ICD-10 classifications
Pure hypercholesterolaemiaLipoprotein deficiencyHyperglycaemia, unspecifiedDisorders of lipoprotein metabolism and other lipidaemiasOther disorders of lipoprotein metabolism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05733325
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05733325 through Pure Global AI's free database. This phase not specified trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and is currently Not yet recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.